Literature DB >> 10448144

Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic.

W S Wold1, K Doronin, K Toth, M Kuppuswamy, D L Lichtenstein, A E Tollefson.   

Abstract

Adenoviruses encode proteins that block responses to interferons, intrinsic cellular apoptosis, killing by CD8(+) cytotoxic T lymphocytes and killing by the death ligands TNF, Fas ligand and TRAIL. The viral proteins are believed to prolong acute and persistent adenovirus infections. The proteins may prove useful in protecting adenovirus gene therapy vectors and transplanted cells from the immune system.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10448144     DOI： 10.1016/S0952-7915(99)80064-8

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  51 in total

Review 1.  The promise and potential hazards of adenovirus gene therapy.

Authors:  L S Young; V Mautner
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 2.  Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.

Authors:  T Hermiston
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

3.  An adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis complexes with dynein and a small GTPase.

Authors:  S A Lukashok; L Tarassishin; Y Li; M S Horwitz
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 4.  Current research on respiratory viral infections: Third International Symposium.

Authors:  A C Schmidt; R B Couch; G J Galasso; F G Hayden; J Mills; B R Murphy; R M Chanock
Journal:  Antiviral Res       Date:  2001-06       Impact factor: 5.970

5.  Characterization of Ad5 E3-14.7K, an adenoviral inhibitor of apoptosis: structure, oligomeric state, and metal binding.

Authors:  Hee-Jung Kim; Mark P Foster
Journal:  Protein Sci       Date:  2002-05       Impact factor: 6.725

6.  Mutations within the ADP (E3-11.6K) protein alter processing and localization of ADP and the kinetics of cell lysis of adenovirus-infected cells.

Authors:  Ann E Tollefson; Abraham Scaria; Baoling Ying; William S M Wold
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

7.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 8.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

9.  Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression.

Authors:  Jackie L Stilwell; Douglas M McCarty; Atsuko Negishi; Richard Superfine; R Jude Samulski
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 10.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.